OBJECTIVES & ACCREDITATION

ACTIVITY TITLE

Optimizing Cardiovascular Risk Reduction in High-Risk Patients Through Lipid Management

ACTIVITY FORMAT

Internet Enduring Material

Fee: There is no fee for this activity. **Release Date:** September 30, 2017 **Expiration Date:** September 30, 2018

national Lipid ASSOCIATION

OVERVIEW

Peter Howard Jones, MD, and **Joseph J. Saseen, PharmD,** provide their insights into the evolving management of patients at high risk of a cardiovascular event despite maximally tolerated statin therapy. Drs. Jones and Saseen review current ACC and NLA guidelines, including recommendations related to the use of nonstatins such as ezetimibe and PCSK9 inhibitors. To facilitate the integration of these guidelines into real-world clinical practice, Drs. Jones and Saseen discuss 4 case scenarios of patients at different levels of cardiovascular risk. These discussions blend evidence from clinical trials with their individual experiences.

TARGET AUDIENCE

This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advanced practice registered nurses, and registered dietitians with an interest in clinical lipidology.

TYPE OF ACTIVITY

Knowledge

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, all participants should be able to:

- Discuss real-world implications of new data on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors;
- Explain the effect of PCSK9 inhibition in specific clinical scenarios (eg, diabetes, familial hypercholesterolemia, statin intolerance):
- Identify patients who may benefit from the use of nonstatin therapies, including PCSK9 inhibitors either as monotherapy or in combination with a statin in order to optimally reduce the risk for atherosclerotic cardiovascular disease (ASCVD);
- Evaluate lipid management treatment plans to reduce ASCVD risk in patients at particularly high risk;
- Discuss strategies to improve the knowledge, skills or performance of the health care team.

CRITERIA FOR SUCCESS

To participate in the activity, go to http://www.annenberg.net/Lipid-Management-CME/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. To receive AMA PRA Category 1 CreditsTM, participants must receive a minimum score of 70% on the posttest.

If you have questions about this CME activity, please contact the NLA at cme@lipid.org. Please claim credit by September 30, 2018.

For pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

COMMERCIAL SUPPORT

This activity is supported by educational funding donation provided by Amgen.

CREDIT DESIGNATION



In support of improving patient care, this activity has been planned and implemented by The National Lipid Association and Annenberg Center for Health Sciences at Eisenhower. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Credit Designation Statement

The National Lipid Association designates this enduring internet activity for a maximum of 2.00 AMA PRA Category 1 $Credits^{\mathsf{TM}}$. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants

NCCPA accepts *AMA PRA Category 1 Credits*™ from organizations accredited by the ACCME.

Dietitians

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 2.0 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002

Pharmacists

Universal Activity Number 0624-9999-17-055-H01-P (Knowledge)

This Activity has been approved for 2.00 contact hour(s) (.2 CEUs) of the Accreditation Council for Pharmacy Education

Nursing

The maximum number of hours awarded for this CE activity is 2.0 contact hours.

FACULTY

Faculty



Houston, Texas

Peter Howard Jones, MD, FACP, FNLA
Medical Director
Weight Management Center
Houston Methodist Hospital
Associate Professor of Medicine
Center for Cardiovascular Disease Prevention
Houston Methodist DeBakey Heart and Vascular
Center
Baylor College of Medicine



Joseph J. Saseen, PharmD, CLS, FNLA Professor and Vice Chair Department of Clinical Pharmacy Professor, Department of Family Medicine University of Colorado Anschutz Medical Campus Aurora, Colorado

FACULTY/PLANNER/STAFF FINANCIAL DISCLOSURES

FACULTY/PLANNER FINANCIAL DISCLOSURES		
Name	Relationship	Company
Jones, Peter	Consultant	Amgen, Merck & Co., Inc., Sanofi/Regeneron
Saseen, Joseph	N/A	Nothing to Disclose
STAFF DISCLOSURES		
Annenberg Center for Health Sciences at Eisenhower	N/A	Nothing to Disclose
NLA	N/A	Nothing to Disclose
NLA CME REVIEWERS		
Dixon, Dave	N/A	Nothing to Disclose

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION

It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

DISCLAIMER

This course is designed solely to provide the health care professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the health care professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader's misunderstanding of content.

PERMISSIONS

The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

ESTIMATED TIME TO COMPLETE

This activity consists of one session, which should take approximately 120 minutes to complete.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Click here for NLA's Privacy Statement.